Cargando…
Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke
BACKGROUND: Previous studies have identified various treatment and patient characteristics that may be associated with higher hospital cost after spontaneous intracerebral hemorrhage (ICH); a devastating type of stroke. Patient morbidity is perhaps the least understood of these cost-driving factors....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553779/ https://www.ncbi.nlm.nih.gov/pubmed/28797241 http://dx.doi.org/10.1186/s12883-017-0930-2 |
_version_ | 1783256672818429952 |
---|---|
author | Specogna, Adrian V. Turin, Tanvir C. Patten, Scott B. Hill, Michael D. |
author_facet | Specogna, Adrian V. Turin, Tanvir C. Patten, Scott B. Hill, Michael D. |
author_sort | Specogna, Adrian V. |
collection | PubMed |
description | BACKGROUND: Previous studies have identified various treatment and patient characteristics that may be associated with higher hospital cost after spontaneous intracerebral hemorrhage (ICH); a devastating type of stroke. Patient morbidity is perhaps the least understood of these cost-driving factors. We describe how hypertension and other patient morbidities affect length of stay, and hospital treatment costs after ICH using primary and simulated data. We also describe the relationship between cost and length of stay within these patients. METHODS: We used a cohort design; evaluating 987 consecutive ICH patients across one decade in a Canadian center. Economic, treatment, and patient data were obtained from clinical and administrative sources. Multimorbidity was defined as the presence of one or more diagnoses at hospital admission in addition to a primary diagnosis of ICH. RESULTS: Hypertension was the most frequent (67%) morbidity within these patients, as well as the strongest predictor of longer stay (adjusted RR for >7 days: 1.31, 95% CI: 1.07-1.60), and was significantly associated with higher cost per visit when accounting for other morbidities (adjusted cost increase for hypertension $8123.51, 95% CI: $4088.47 to $12,856.72 USD). A Monte Carlo simulation drawing one million samples of patients estimated for a generation (100 years) assuming 0.94% population growth per year, and a hospitalization rate of 12 per 100,000 inhabitants, supported these findings (p = 0.516 for the difference in unadjusted cost: simulated vs primary). Using a restricted cubic spline, we observed that the rate of change in overall cost for all patients was greatest for the first 3 weeks (p < 0.001) compared to subsequent weeks. CONCLUSION: Patient multimorbidity, specifically hypertension, is a strong predictor of longer stay and cost after ICH. The non-linear relationship between cost and time should also be considered when forecasting healthcare spending in these patients. |
format | Online Article Text |
id | pubmed-5553779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55537792017-08-15 Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke Specogna, Adrian V. Turin, Tanvir C. Patten, Scott B. Hill, Michael D. BMC Neurol Research Article BACKGROUND: Previous studies have identified various treatment and patient characteristics that may be associated with higher hospital cost after spontaneous intracerebral hemorrhage (ICH); a devastating type of stroke. Patient morbidity is perhaps the least understood of these cost-driving factors. We describe how hypertension and other patient morbidities affect length of stay, and hospital treatment costs after ICH using primary and simulated data. We also describe the relationship between cost and length of stay within these patients. METHODS: We used a cohort design; evaluating 987 consecutive ICH patients across one decade in a Canadian center. Economic, treatment, and patient data were obtained from clinical and administrative sources. Multimorbidity was defined as the presence of one or more diagnoses at hospital admission in addition to a primary diagnosis of ICH. RESULTS: Hypertension was the most frequent (67%) morbidity within these patients, as well as the strongest predictor of longer stay (adjusted RR for >7 days: 1.31, 95% CI: 1.07-1.60), and was significantly associated with higher cost per visit when accounting for other morbidities (adjusted cost increase for hypertension $8123.51, 95% CI: $4088.47 to $12,856.72 USD). A Monte Carlo simulation drawing one million samples of patients estimated for a generation (100 years) assuming 0.94% population growth per year, and a hospitalization rate of 12 per 100,000 inhabitants, supported these findings (p = 0.516 for the difference in unadjusted cost: simulated vs primary). Using a restricted cubic spline, we observed that the rate of change in overall cost for all patients was greatest for the first 3 weeks (p < 0.001) compared to subsequent weeks. CONCLUSION: Patient multimorbidity, specifically hypertension, is a strong predictor of longer stay and cost after ICH. The non-linear relationship between cost and time should also be considered when forecasting healthcare spending in these patients. BioMed Central 2017-08-10 /pmc/articles/PMC5553779/ /pubmed/28797241 http://dx.doi.org/10.1186/s12883-017-0930-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Specogna, Adrian V. Turin, Tanvir C. Patten, Scott B. Hill, Michael D. Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke |
title | Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke |
title_full | Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke |
title_fullStr | Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke |
title_full_unstemmed | Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke |
title_short | Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke |
title_sort | hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553779/ https://www.ncbi.nlm.nih.gov/pubmed/28797241 http://dx.doi.org/10.1186/s12883-017-0930-2 |
work_keys_str_mv | AT specognaadrianv hospitaltreatmentcostsandlengthofstayassociatedwithhypertensionandmultimorbidityafterhemorrhagicstroke AT turintanvirc hospitaltreatmentcostsandlengthofstayassociatedwithhypertensionandmultimorbidityafterhemorrhagicstroke AT pattenscottb hospitaltreatmentcostsandlengthofstayassociatedwithhypertensionandmultimorbidityafterhemorrhagicstroke AT hillmichaeld hospitaltreatmentcostsandlengthofstayassociatedwithhypertensionandmultimorbidityafterhemorrhagicstroke |